What Are Intranasal Corticosteroids?
Intranasal corticosteroids are topically-applied steroid medications delivered directly to the nasal mucosa via spray or aerosol formulations, representing the most effective medication class for controlling all four major symptoms of allergic rhinitis: sneezing, itching, rhinorrhea, and nasal congestion. 1
Mechanism and Formulations
Intranasal corticosteroids work primarily through anti-inflammatory activity by reducing proinflammatory mediators, cytokines, and inflammatory cells in the nasal mucosa 1, 2. The concept behind their development was to deliver corticosteroids locally to nasal airways, achieving adequate drug concentrations at receptor sites while minimizing systemic side effects that occur with oral or parenteral corticosteroids 1, 3.
Available formulations include:
- Beclomethasone dipropionate
- Budesonide
- Flunisolide
- Fluticasone propionate
- Fluticasone furoate
- Mometasone furoate
- Triamcinolone acetonide 1, 3
Clinical Efficacy Profile
Intranasal corticosteroids are superior to oral antihistamines, leukotriene receptor antagonists, and even the combination of antihistamines plus leukotriene antagonists for treating allergic rhinitis 1. They demonstrate:
- Onset of action: 3-12 hours, with some patients experiencing relief as early as 3-4 hours 1
- Symptom control: Effective for all nasal symptoms (congestion, rhinorrhea, sneezing, itching) and may provide some benefit for associated eye symptoms 1
- Comparative effectiveness: More effective than nasal cromolyn and intranasal anticholinergics (except for pure rhinorrhea) 1
Clinical Indications
Beyond allergic rhinitis, intranasal corticosteroids are useful for:
- Nonallergic rhinitis, particularly NARES (nonallergic rhinitis with eosinophilia syndrome) and vasomotor rhinitis 1
- Severe or persistent rhinitis requiring first-line treatment without prior antihistamine trials 1
Safety Profile
When given in recommended doses, intranasal corticosteroids are not generally associated with clinically significant systemic side effects 1. This favorable safety profile stems from:
- Low systemic bioavailability: Newer agents (fluticasone propionate, mometasone furoate, fluticasone furoate) have negligible systemic absorption, while older agents (flunisolide, beclomethasone, triamcinolone, budesonide) have higher bioavailability (34-49%) 4
- No HPA axis suppression: Studies in both adults and children show no clinically significant effects on hypothalamic-pituitary-adrenal axis function at recommended doses 1
- No bone density effects: No reduction in bone density has been reported 1
Local Side Effects and Prevention
Common local adverse effects occur in 5-10% of patients and include 1, 3:
- Nasal irritation, dryness, burning, stinging
- Epistaxis (nosebleeds)
- Headache
Critical prevention strategy: Patients must be instructed to direct sprays away from the nasal septum to prevent mucosal erosions and the rare complication of nasal septal perforation 1. The nasal septum should be periodically examined for mucosal erosions, which may indicate increased perforation risk 1.
Pediatric Considerations
In children, intranasal corticosteroids should be used at the lowest effective dose 1. While growth suppression has been reported with long-term use of beclomethasone dipropionate exceeding recommended doses, studies with fluticasone propionate, mometasone furoate, and budesonide at recommended doses show no effect on growth compared to placebo 1. Growth effects may be a more sensitive indicator of systemic exposure than HPA axis testing in children 1.
Practical Use Guidelines
Intranasal corticosteroids may be considered for initial treatment without requiring a previous trial of antihistamines or oral decongestants, and should always be considered before initiating systemic corticosteroids 1.
Dosing Strategies
- Regular daily use: Most effective approach for symptom control 1
- As-needed use: Can provide significant relief (shown with fluticasone propionate), though may be less effective than continuous use 1
Optimization Tips
- If nasal congestion prevents adequate delivery, use a nasal decongestant spray for several days when initiating intranasal corticosteroids to ensure patent nasal airways 1
- Maximum efficacy typically achieved with consistent use over time
Product Equivalence
The overall clinical response does not appear to vary significantly between available intranasal corticosteroid products, despite differences in topical potency, lipid solubility, and receptor binding affinity 1. However, newer agents with lower systemic bioavailability may be theoretically preferable, particularly for patients on multiple corticosteroid therapies 5, 4.